DOCSLIB.ORG

Brief Review of Studies on Oral Martial Therapy Compared to the Administration of Intravenous Iron in Nephrology and Dialysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brief Review of Studies on Oral Martial Therapy Compared to the Administration of Intravenous Iron in Nephrology and Dialysis ARC Journal of Nephrology Volume 3, Issue 2, 2018, PP 6-8 www.arcjournals.org Brief Review of Studies on Oral Martial Therapy Compared to the Administration of Intravenous Iron in Nephrology and Dialysis Ennio Duranti1*, Diletta Duranti2 1Consultant Nephrologist, Arezzo, Italy 2DepartmentPathology and ClinicalLaboratories AUO Novara, Italy *Corresponding Author: Ennio Duranti, Consultant Nephrologist, Arezzo, Italy, Email: [email protected] Anemia is a frequent and early complication of 20% of the administered iron is absorbed Chronic Kidney Disease (CKD), and its [10,11]. The sophisticated technology of natural prevalence increases with the worsening of renal phospholipids mounting makes the highly function, involving over 50% of patients in bioavailable iron, well tolerated and rapidly predialysis (stage 4 - 5) and practically almost absorbed. The presence of liposomal wrapper, 100% of patients in hemodialysis [1]. The in fact, protecting the iron by contact with the anemic state depends on an inadequate gastric mucosa avoids the pro-oxidant effect of production of erythropoietin, however a free iron. Liposomal protection allows the fundamental importance is represented by the micro-nutrient to overcome harmless the gastric alterations of the martial state or due to an iron environment to be absorbed directly in the small deficiency, as a consequence of inadequate intestine and not only in duodenum. Liposome intestinal absorption, or due to reduced technology delivery corresponds, in our body, bioavailability, linked to the systemic to the transport of various substances from the inflammatory state, characteristic of these chylomicrons. These vehicles are few crowded patients or for uremic toxicity [2]. The natural and voluminous lipoproteins that administration of oral or intravenous iron and represent the mode of transport of dietary fats erythropoietin (Epo) is a key element for the from the intestine to the various tissues. This correction of anemia both in patients with CKD similarity between liposomes and chylomicrons and in patients on chronic hemodialysis [3,4]. enables liposomal molecules to exploit same The martial therapy, administered orally is metabolic pathways that the body usually enacts preferred in patients in the conservative phase, to chylomicrons. In the intestinal lumen, the but presents frequent side effects especially of liposome is absorbed directly from M cells gastrointestinal type. In contrast, hemodialysis (enterocytes) that originate from the lymphatic patients use almost exclusively the intravenous system and are located on all the small intestine. route that can promote even serious allergic Then the liposome is incorporated for phenomena, and can lead to an increase in the endocytosis by macrophages and through the systemic inflammation with consequent lymphatic stream reaches, intact hepatocytes functional anemia due to a reduced use of the [8,13]. Within the hepatocytes, liposomes are iron by the marrow [3,4]. The possibility of opened by lysosomal enzymes, making iron having a particular oral iron preparation, the available to the organism. So in patients with liposomaliron, based on ferric pyrophosphate conservative CKD oral iron administration is carried within a phospholipid membrane, preferred, but sometimes for intestinal appears to have a lower incidence of malabsorption or the appearance of side effects, gastrointestinal side effects, without increasing such as abdominal pain, gastralgia, nausea, the inflammation of the patient [5]. Ionic iron vomiting, diarrhea, we are forced to pass to the absorption takes place predominantly in administration via intravenous [6]. As duodenal level and is mediated by specific mentioned early, in patients on chronic carriers: ionic iron enters the intestinal cells by hemodialysis, intravenous iron during dialysis means of a divalent metal transporter. The session, is preferred for practical reasons. transition to the blood stream is then mediated However, allergic phenomena may occur up to by ferroportin at the basolateral membrane of severe anaphylactic reactions, potential the enterocyte; in normalconditions only 15- cytotoxicity, hepatic disease with iron ARC Journal of Nephrology Page | 6 Brief Review of Studies on Oral Martial Therapy Compared to the Administration of Intravenous Iron in Nephrology and Dialysis accumulation in various forms of liposomal microencapsulation, for which iron hemochromatosis, an increased risk of does not come into contact with mucous developing cirrhosis with levels of ferritin > membranes with better intestinal absorption 1000 ng / ml and an increase in the systemic bypassing the block induced by hepcidin, inflammation with a decrease in antioxidant moreover the absorbed pyrophosphate iron has a defenses [7]. The increased production of greater affinity for the transferrin and is directly inflammatory markers, such as CRP, IL-6, TNF- transferred to the bone marrow [5]. In this alpha, promotes the release of hepcidin, a regard we have conducted a study [12], on a protein produced by the liver that acts by small number of patients in chronic daily home binding to another protein, called ferroportin, hemodialysis (8 pts) and on a group in which regulates the escape of iron from cells , conservative therapy with chronic renal failure blocking the passage of iron from cells to blood Stage 3b-4 (16pts) who were on treatment for resulting in functional iron deficiency, so-called sideropenic anemia: all pts belonging to the two inflammatory anemia [8,9,15]. Furthermore, groups had been earlier treated for at least 6 recently they have been emphasized the medico- months, with carboxymaltose iron iv (500 legal issues related to intravenous iron mg/month) and after they were passed to oral administration: a recent note dated 25 October liposomal iron. The protocol lasted 6 months for 2013 from the Italian Medicines Agency (AIFA) home hemodialys is pts and 12 months for CKD (www.agenzia droga.gov.it) underlined the risk pts. The study showed the equivalent efficacy of of intravenous administration with potentially oral liposomal iron, compared to intravenous fatal reactions, especially in patients with known iron, with the maintenance and in many cases allergies and in patients with inflammatory favoring the increment of hemoglobin values diseases, including the immune system, as well and reducing or keeping the same as in patients with asthma, eczema, atopic Erythropoietin dosages. These results confirmed allergies [1, 10]. Therefore, according to these previously performed nephrological works notes, hemodialysis patients undergoing including a previous our work performed in 10 intravenous therapy should be monitored closely patients on three weekly dialysis treatment [10- during and at least 30 minutes after 14]. Differently from the precedent study the os administration in the presence of a doctor, in iron period was compared to an iv gluconate addition to the nursing staff, and all this could iron period. The period (3months) of liposomal create organizational problems of considerable iron intake showed a significant increase in complexity especially if such indications should terms of Hb concentration, transferrin saturation be extended to the Dialysis Centers for limited and a significant decrease regarding CRP values and / or decentralized assistance, where the and weekly consumption of Epo. While the presence of the doctor is notoriously returning to iv gluconate iron administration circumscribed at times that do not cover all the period showed a significant reduction of Hb, a dialysis sessions of the day. Although on one significant increase in the weekly consumption hand, among the various preparations, iron of Epo and increase of CRP. The conclusion of gluconate and carboxymaltose seem to be the these two our studies [12, 14] was that one with fewer side effects, the Work Group liposomal iron seems to be a valid alternative to KDIGO 2012 did not show a definite benefit of intravenous iron therapy (iron gluconate o the intravenous route compared to the oral [1]. carboxymaltose). A particularly interesting On the other hand, as already mentioned, the use aspect of these studies is the reduction of PCR: of old oral iron compounds has not had much statistically significant in the first experience development until now due to their low efficacy and not statistically significant in the second and to the gastroenteric side effects linked to the experience of these two different works. This compound which usually contains iron sulphate, positive effect is explained by a lower activation which can be used only for a limited range of / production of inflammatory markers that patients, certainly not affected by Chronic Renal increase with the use of intravenous iron Insufficiency, since in these patients gastritis through the production of the species of reactive and gastralgia are constant [6]. So recently, the oxygen that exacerbate systemic inflammation, possibility of having a particular oral iron with decreased antioxidant defenses and preparation, the liposomal iron, based on ferric increased TNF and IL-6 release [15]. The pyrophosphate carried within a phospholipid absence of these inflammation effects in the membrane, showed a lower incidence of case of the use of liposomal iron, also explains gastrointestinal side effects, thanks to the the maintenance of weekly doses of ARC Journal of Nephrology Page | 7 Brief Review of Studies on Oral Martial Therapy Compared to the Administration of Intravenous Iron in
Load more

Recommended publications
  • Intravenous Therapy Procedure Manual
    INTRAVENOUS THERAPY PROCEDURE MANUAL - 1 - LETTER OF ACCEPTANCE __________________________________________ hereby approves (Facility) the attached Reference Manual as of _____________________. (Date) The Intravenous Therapy Procedure Manual will be reviewed at least annually or more often when deemed appropriate. Revisions will be reviewed as they occur. Current copies of the Intravenous Therapy Procedure Manual shall be maintained at each appropriate nursing station. I have reviewed this manual and agree to its approval. __________________________ (Administrator) __________________________ (Director of Nursing) __________________________ (Medical Director) - 2 - TABLE OF CONTENTS TABLE OF CONTENTS INTRODUCTION A. Purpose 1 B. Local Standard of Practice 1 RESPONSIBILITIES A. Responsibilities: M Chest Pharmacy 1 B. Responsibilities: Administrator 1 C. Responsibilities: Director of Nursing Services (DON/DNS) 1 D. Skills Validation 2 AMENDMENTS GUIDELINES A. Resident Candidacy for IV Therapy 1 B. Excluded IV Medications and Therapies 1 C. Processing the IV Order 1 D. IV Solutions/Medications: Storage 2 E. IV Solutions/Medications: Handling 3 F. IV Solutions and Supplies: Destroying and Returning 4 G. IV Tubing 5 H. Peripheral IV Catheters and Needles 6 I. Central Venous Devices 7 J. Documentation and Monitoring 8 K. IV Medication Administration Times 9 L. Emergency IV Supplies 10 I TABLE OF CONTENTS PROTOCOLS A. IV Antibiotic 1 1. Purpose 2. Guidelines 3. Nursing Responsibilities B. IV Push 2 1. Purpose 2. Guidelines C. Anaphylaxis Allergic Reaction 4 1. Purpose 2. Guidelines 3. Nursing Responsibilities and Interventions 4. Signs and Symptoms of Anaphylaxis 5. Drugs Used to Treat Anaphylaxis 6. Physician Protocol PRACTICE GUIDELINES A. Purpose 1 B. Personnel 1 C. Competencies 1 D.
    [Show full text]
  • Attachment 3
    CURRICULUM CLINICAL BASE / CA-1 / CA-2 / CA-3 ANESTHESIOLOGY RESIDENCY PROGRAM GOALS AND OBJECTIVES AND CORE COMPETENCIES Department of Anesthesiology University of Missouri at Kansas City School of Medicine Saint Luke’s Hospital Truman Medical Center Children’s Mercy Hospital Revised 2011 Table of Contents Pages Introduction – Statement of Curriculum ................................................................................................................... 3 I. Rendering Patient Insensible to Pain ............................................................................................................. 4-10 II. Support of Life Functions ............................................................................................................................. 11-16 III. Clinical Base Year A. Cardiology ................................................................................................................................................. 17-32 B. Emergency Medicine ................................................................................................................................. 33-44 C. General Medicine ....................................................................................................................................... 45-49 D. Infectious Disease ...................................................................................................................................... 50-59 E. Nephrology ..............................................................................................................................................
    [Show full text]
  • Nicotine Patches Appear Safe for CAD Patients
    May 1, 2007 • www.internalmedicinenews.com Cardiovascular Medicine 37 Nicotine Patches Appear Safe for CAD Patients BY BRUCE JANCIN 30%, but many physicians have been re- induced myocardial defect on single-photon ment arm jumped from 10.9 to 25.2 Denver Bureau luctant to recommend it for their patients emission computed tomography (SPECT) ng/mL, Dr. Leja said. After 1 week, patients with coronary artery disease (CAD) be- to receive either 21-mg nicotine patches or were encouraged to quit smoking while N EW O RLEANS — Nicotine patches cause nicotine is known to increase heart placebo in addition to continuing their usu- continuing to use their assigned patches. are safe for use in smokers with known rate and blood pressure, and can induce al amount of cigarette smoking. The pri- Upon SPECT imaging at week 4, the coronary artery disease and stress-induced vasoconstriction as well, Dr. Monika J. Leja mary end point of the study was change in size of the perfusion defects in the nico- myocardial ischemia, according to the re- reported at the annual scientific session of total perfusion defect size upon repeat stress tine patch group remained unchanged sults of the first-ever randomized, place- the American College of Cardiology. SPECT imaging performed at 1 week. from baseline, although their plasma nico- bo-controlled, multicenter clinical trial to Dr. Leja and her coinvestigators at the There was no change in the total or is- tine levels remained as high as at week 1. examine this issue. Methodist DeBakey Heart Center in Hous- chemic perfusion defect size, compared The trial was supported by Glaxo- Nicotine replacement therapy doubles ton randomized 55 heavy smokers with with baseline, in either group even though SmithKline Consumer Healthcare.
    [Show full text]
  • Intravenous Infusion Drug Administration: Flushing Guidance
    Intravenous Infusion Drug Administration: Flushing Guidance April 2019 Acknowledgements: Andrew Barton – Author/reviewer NIVAS Chair Advanced Nurse Practitioner, IV Therapy and Vascular Access Frimley Health NHS Foundation Trust Tim Jackson – Reviewer/contributor, NIVAS Board Deputy Chair Consultant in Anesthesia & Intensive Care Medicine Calderdale & Huddersfield NHS Foundation Trust Gemma Oliver - Reviewer/contributor NIVAS Board Nurse Consultant, Integrated IV Care East Kent Hospitals NHS Foundation Trust Nicola York - Reviewer/contributor NIVAS Board Clinical Nurse Manager Vascular Access and Nutrition support Oxford University Hospitals NHS Foundation Trust Matt Jones - Reviewer/contributor NIVAS Board Consultant Anaesthetist East Kent Hospitals NHS Foundation Trust Steve Hill - Reviewer/contributor NIVAS Board Procedural Team Manger The Christie NHS Foundation Trust Marie Woodley - Reviewer/contributor NIVAS Board Clinical Nurse Specialist IV therapy/OPAT Lead Buckinghamshire Healthcare Trust Contents: Introduction………………………………………………………………………… Page 1 Methods of administering intravenous therapy………………………………… Page 2 Intravenous bolus injection…………………………………………….… Page 2 Continuous, variable dose syringe driver injection……………………. Page 2 Intravenous infusion…………………………………………………….… Page 3 Option 1: Discarding the infusion set………………………………….… Page 3 Option 2: Flushing the Infusion set manually…………………………... Page 4 Option 3: Flushing the infusion set with a closed system…………….. Page 4 General Guidance…………………………………………………………………. Page 5 Conclusion………………………………………………………………………….
    [Show full text]
  • Intravenous Therapytherapy
    IntravenousIntravenous TherapyTherapy Department of EMS Professions Temple College IVIV TherapyTherapy OverviewOverview I DefinitionsDefinitions && IndicationsIndications I FluidFluid ResuscitationResuscitation I EquipmentEquipment andand SuppliesSupplies I ChoosingChoosing FluidsFluids andand CathetersCatheters I ProcedureProcedure andand TechniqueTechnique TipsTips – Peripheral Venipuncture – Intraosseous Access I PotentialPotential ComplicationsComplications DefinitionsDefinitions I IVIV // VenipunctureVenipuncture I CrystalloidsCrystalloids I PeripheralPeripheral // CentralCentral I ColloidsColloids I IntraosseousIntraosseous AccessAccess I HypertonicHypertonic I FluidFluid ResuscitationResuscitation I IsotonicIsotonic I MedicationMedication AccessAccess I DripDrip RatesRates I KVOKVO // TKOTKO IndicationsIndications forfor VenipunctureVenipuncture I VolumeVolume I VenousVenous AccessAccess toto – Dehydration CirculationCirculation I Water – Blood collection I Electrolytes I Labs – Blood Loss I Field Chemistry I Colloids – Medication I Crystalloids Administration FluidFluid ResuscitationResuscitation I DehydrationDehydration andand I ShockShock VolumeVolume LossLoss ManagementManagement – Replace Lost Fluid or – Controversial Blood – Definitive therapy = – Often requires 2 -3 Surgery and blood times the amount replacement lost (2:1 rule) – EMS → judicious replacement – Improve end organ perfusion (BP at 90 - 100 mm Hg) EquipmentEquipment andand SuppliesSupplies I FluidsFluids I SuppliesSupplies – Normal Saline – IV Catheters (0.9%
    [Show full text]
  • Intravenous Medicine Administration Self-Directed Learning Package
    Acute Services Division Practice Development Department Intravenous Medicine Administration Self-directed Learning Package Margaret A. Connolly Katherine Hill Lynne Robertson Debbie Thompson Pinky Virhia First published August 2007 Revised July 2014 For review July 2016 Contribution by Christina Ronyane © Practice Development Department, NHS Greater Glasgow and Clyde 2014. All rights reserved. No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying,recording or otherwise without the prior permission of Practice Development Department, NHS GG&C. Acknowledgement of sources of illustrations Figure 1 – page 7 Yellow Card Reproduced with the kind permission of the MHRA. Figure 2 – page 9 Peripheral venous access. Reproduced with the kind permission of Smith and Nephew. Figure 3 – page 10 Midline. Images provided by Vygon (UK) Ltd – © Vygon (UK) Ltd 2012. Figure 4 – page 10 Peripherally inserted central catheter. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 5 – page 10 Non Skin Tunnelled Central Line. Reproduced with the kind permission of Smith and Nephew. Figure 6 – page 11 Skin Tunnelled central venous access. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 7 – page 11 Indwelling Central Venous Access Device. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 10 – page 19 Anaphylaxis algorithm - Reproduced with the kind permission of the Resuscitation Council (UK). Contents Prerequisites for undertaking the IV
    [Show full text]
  • Improvement of Biodistribution with Pegylated Liposomes Containing
    ANTICANCER RESEARCH 31: 153-160 (2011) Improvement of Biodistribution with PEGylated Liposomes Containing Docetaxel with Degradable Starch Microspheres for Hepatic Arterial Infusion in the Treatment of Liver Metastases: A Study in CC-531 Liver Tumor-bearing WAG RIJ Rats U. POHLEN, H.J. BUHR and G. BERGER Department of Surgery, Charité Universitaetsmedizin Berlin, Benjamin Franklin Campus, Berlin, Germany Abstract. Aim: To improve the drug concentration in liver metastatic breast cancer develop liver metastases and have a metastases, docetaxel was encapsulated in polyethyleneglycol- poor prognosis, with a median survival of 1-2 years and a 5- liposomes and administered regionally with degradable starch year survival rate of approximately 20% (6, 7). microspheres (DSM). Materials and Methods: A rodent model The most frequently applied chemotherapeutic agent for of solitary metastasis (CC-531 adenocarcinoma) was studied. advanced breast cancer, ovarian cancer and gastric cancer is The animals were randomized into six groups and treated with docetaxel (8-10). 15 ng/kg docetaxel: I: intravenous (i.v.). II: PEG-liposomes Docetaxel inhibits cell proliferation by inducing a i.v.; III: intraartial (i.a.) via the hepatica artery; IV: i.a.) + sustained mitotic block at the metaphase/anaphase anticancer DSM; V: PEG-liposomes i.a.; and VI: PEG-liposomes i.a. + agents in this class promote the polymerization of stable DSM. The docetaxel concentration in the serum, liver and liver microtubules, inhibit their disassembly and profoundly affect tumor at defined times (5, 15, 30, 60,120 240 min and 24 h) a number of key cellular functions that depend on the was measured using HPLC.
    [Show full text]
  • Improving Intravenous Therapy: Opportunities for Designing the Next Generation Infusion System Part 3 – Workflow Efficiency & Cost-Effectiveness
    IMPROVING INTRAVENOUS THERAPY: OPPORTUNITIES FOR DESIGNING THE NEXT GENERATION INFUSION SYSTEM PART 3 – WORKFLOW EFFICIENCY & COST-EFFECTIVENESS AUTHORED BY: Matthew B. Weinger, MD, MS Andrew Kline, BA Department of Anesthesiology, Vanderbilt University School of Medicine INTRODUCTION In this three-part series, we strive to provide an overview of the current status and apparent effectiveness from the user’s point- of-view of infusion pump design. We acknowledge the advances in the field while highlighting opportunities for future improvements. In focusing on some of the usability issues of current pump interfaces and insufficient interoperability, we highlight some of the existing pitfalls and offer human factors-based guidance for next-generation designs. Here, we define infusion pump usability as the relationship We focus on issues related to the between the technology and clinicians’ ability to use that technology general usability, process efficiency and to attain their work goals effectively, safely, efficiently, and with both clinician and patient satisfaction. cost effectiveness of infusion pump use. In this, the third part of the series, we focus on issues related to the general usability, process efficiency and cost effectiveness of infusion pump use. We also address current shortcomings of the integration of infusion pump technology with medication management software. 1 Workflow Efficiency and Cost Effectiveness An important added benefit of optimal pump designs is the prospect of significant cost savings. Each preventable ADE has been reported to cost nearly $9,000,[1] and smart pumps could, through built-in designs to adhere to the “Rights,” decrease the incidence of ADEs (see Part 1 of this series for more information on this topic).
    [Show full text]
  • Intravenous Therapy
    Intravenous therapy What is an intravenous? An intravenous is a thin, plastic tube called a catheter that is put into a vein to give you fluid. The catheter is attached to a solution bag hanging on a pole. This is all called an IV. The type of solution you have depends on your special needs. The IV needs to go into a vein so the blood can carry the fluid around your body. Most often, the IV is put in your hand or forearm. An IV can be put in a foot, upper arm or inner elbow. You may have an IV lock called a saline lock. This means that the catheter is attached to a very short tube with a cap. When it is time for fluid or medication, the cap is taken off and the catheter is attached to a longer tube and solution. This is most often done if you need an IV for medications but do not need extra fluid. Why do I need an IV? There are many reasons for having an IV. Here are some reasons: to give fluids to give medication to give blood or blood products please turn over Intravenous therapy What is an IV pump? Your IV may be connected to an IV pump. The nurses program the pump to deliver the right amount of medications and fluids. It will beep or alarm for different reasons. What activities can I do with an IV? After the IV is put in, there is no needle left in your vein. The tube is held in your vein with tape.
    [Show full text]
  • (Not for IV Bolus Injection) RX ONLY ERAXIS™ (Anidulafungin
    NDA 21-632/S-010 Page 6 [INTRAVENOUS INFUSION, DILUTED WITH STERILE WATER FOR INJECTION] (not for IV Bolus Injection) RX ONLY ERAXIS™ (anidulafungin) FOR INJECTION DESCRIPTION ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4­ yl]carbonyl]-L-ornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 50 mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125 mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. 100 mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250 mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. The empirical formula of anidulafungin is C58H73N7O17 and the formula weight is 1140.3. The structural formula is: H H OH O HO OC5H11 H O NH HO NH O H C H 3 HN CH N 3 H O H HO O H OH H NH N H3C H H OH HO N O H H H O OH H H OH Prior to administration, ERAXIS for Injection requires reconstitution with sterile Water for Injection and subsequent dilution with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline).
    [Show full text]
  • IV Infusion Therapy Forms
    Intravenous (IV) Infusion Therapy Checklist of what to bring: Your completed Intravenous (IV) Therapy Intake Form A copy of your most recent bloodwork (including G6PD) is helpful Your signed Consent Form Make sure that you are well hydrated prior to your visit; we suggest drinking one to two 16oz. bottles of water. Dehydration can make it difficult to insert an IV. Make sure you eat something prior to you visit; we suggest a high protein snack, such as nuts, seeds, a protein bar, cheese, yogurt, or eggs. Low blood sugar can make you feel weak, light-headed, or dizzy. During your first visit for IV Therapy infusions: During the first visit, the healthcare practitioner will discuss your symptoms and desired outcomes. Based on this assessment, your IV infusion will be customized to address your needs. If you have any complex medical conditions, the healthcare practitioner may request that you obtain blood work and/or your PCP’s approval prior to administering any IV infusions. What to eXpect: The IVs used during your Intravenous (IV) infusion therapy are eXactly the same that you would find in a hospital. Instead of a clinical eXperience though, our IV infusions are given in a peaceful spa setting and leave you feeling calm, relaXed, and refreshed. Depending on your customized IV cocktail, the infusion can be finished in as little as 20- 30 minutes. Our friendly and attentive staff will keep you calm, cared for, and comfortable during your infusion. Patients find the eXperience tranquil and healing. Patients leave feeling vibrant, energized, and refreshed. Flatiron Functional Medicine 400 S.
    [Show full text]
  • Home Health Care (For Nebraska Only) – Community Plan Coverage
    UnitedHealthcare® Community Plan Coverage Determination Guideline Home Health Care (for Nebraska Only) Guideline Number: CS137NE.O Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Related Community Plan Policies Application ..................................................................................... 1 • Home Hemodialysis (for Nebraska Only) Coverage Rationale ....................................................................... 1 • Private Duty Nursing (PDN) Services (for Nebraska Definitions ...................................................................................... 2 Only) Applicable Codes .......................................................................... 3 • Skilled Care and Custodial Care Services (for References ................................................................................... 11 Nebraska Only) Guideline History/Revision Information ..................................... 11 Instructions for Use ..................................................................... 11 Commercial Policy • Home Health Care Medicare Advantage Coverage Summary • Home Health Services and Home Health Visits Application This Coverage Determination Guideline only applies to the state of Nebraska. Coverage Rationale Indications for Coverage The services being requested must meet all of the following criteria: A written treatment plan must be submitted with the request for specific services and supplies. Periodic review of the written treatment plan may be required for continued Skilled
    [Show full text]